Please assess the completion status of the following clinical trial:

Trial Title: Crizanlizumab for Treating COVID-19 Vasculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing to provide written informed consent~2. Willing to comply with all study procedures and be available for the duration of the study~3. Male or female ≥ 18 years of age~4. SARS-CoV-2 infection (COVID-19) within the past 10 d documented by laboratory test (nucleic acid test (NAT) or reverse transcriptase-polymerase chain reaction (RT-PCR))~5. Currently hospitalized~6. Symptoms of acute respiratory infection (at least one of the following: cough, fever \> 37.5°C, dyspnea, sore throat, anosmia),~7. Radiographic evidence of pulmonary infiltrates~8. Requiring supplemental oxygen or the peripheral capillary oxygenation saturation (SpO2) \< 94% on room air at screening~9. Elevated D-Dimer \> 0.49 mg/L~10. Negative pregnancy test for females of childbearing potential~Exclusion Criteria:~1. Use of home oxygen at baseline~2. Current use of mechanical ventilation~3. Inability to provide consent~4. Do not intubate status~5. Prisoner or incarcerated~6. Pregnancy or Breast Feeding~7. Participation in other interventional therapy trials for COVID-19.~8. International normalized ratio (INR) \> 3 or activated partial thromboplastin time (aPTT) \> 60

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crizanlizumab (Type: EXPERIMENTAL): Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
- Placebo Saline (Type: ACTIVE_COMPARATOR): 0.9% saline 100 ml IV once.

Based on this trial design, predict the completion outcome and termination type (if applicable).